Thumbnail Image
Item

Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)

Mullens, Wilfried
; 
Dauw, Jeroen
; 
Gustafsson, Finn
; 
Mebazaa, Alexandre
; 
Steffel, Jan
; 
Witte, Klaus K.
; 
Delgado, Victoria
; 
Linde, Cecilia
; 
Vernooy, Kevin
; 
Anker, Stefan D.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Author
Mullens, Wilfried
Dauw, Jeroen
Gustafsson, Finn
Mebazaa, Alexandre
Steffel, Jan
Witte, Klaus K.
Delgado, Victoria
Linde, Cecilia
Vernooy, Kevin
Anker, Stefan D.
Chioncel, Ovidiu
Milicic, Davor
Hasenfuss, Gerd
Ponikowski, Piotr
Stephan von Bardeleben, Ralph
Koehler, Friedrich
Ruschitzka, Frank
Damman, Kevin
Schwammenthal, Ehud
Testani, Jeffrey M.
Zannad, Faiez
Böhm, Michael
Cowie, Martin R.
Dickstein, Kenneth
Jaarsma, Tiny
Filippatos, Gerasimos
Volterrani, Maurizio
Thum, Thomas
Adamopoulos, Stamatis
Cohen-Solal, Alain
Moura, Brenda
Rakisheva, Amina
Ristic, Arsen
Bayes-Genis, Antoni
Van Linthout, Sophie
Tocchetti, Carlo Gabriele
Savarese, Gianluigi
Skouri, Hadi
Adamo, Marianna
Amir, Offer
Yilmaz, Mehmet Birhan
Simpson, Maggie
Tokmakova, Mariya
González, Arantxa
Piepoli, Massimo
Seferovic, Petar
Metra, Marco
Coats, Andrew J. S.
Rosano, Giuseppe M. C.
Abstract
Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter-defibrillators and long-term mechanical support. For others, more evidence is still needed before large-scale implementation can be strongly advised. Of note, devices and drugs can work synergistically in HF as improved disease control with devices can allow for further optimization of drug therapy. Therefore, some devices might already be considered early in the disease trajectory of HF patients, while others might only be reserved for advanced HF. As such, device therapy should be integrated into HF care programmes. Unfortunately, implementation of devices, including those with the greatest evidence, in clinical care pathways is still suboptimal. This clinical consensus document of the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) describes the physiological rationale behind device-provided therapy and also device-guided management, offers an overview of current implantable device options recommended by the guidelines and proposes a new integrated model of device therapy as a part of HF care.
Keywords
heart failure, device therapy
Date
2024
Type
Journal article
Journal
European Journal of Heart Failure
Book
Volume
26
Issue
2
Page Range
483-501
Article Number
ACU Department
Faculty of Health Sciences
Collections
Faculty of Health Sciences - General
Show all metadata
URI
https://hdl.handle.net/20.500.14802/34957
Relation URI
DOI
10.1002/ejhf.3150
Source URL
Event URL
Open Access Status
Open access
License
All rights reserved
File Access
Controlled
Notes
Bronze open access.